hotspot -WSS

hotspot

author：knowledge 2025-09-02 17:49:52 - browse：4

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： PBMs drew scrutiny in House hearing — and so did pharma

Wikipedia

hotspot

WSS

Akili changes sales model for its ADHD video game treatment

SCOTUS to consider access to abortion pill mifepristone

AI models in health care face new federal disclosure requirements

STAT letters to the editor on burnt

House panel takes first step toward fixing drug shortages

People with substance use disorder deserve online privacy

focus

hotspot

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

White House Covid adviser calls on docs to combat misinformation

Malaria cases in Florida and Texas: Here’s what you need to know

What happened to the House vote on health price transparency?

Affirmative action in medical school literally saved lives

Why the quest to eradicate polio has stumbled

Alkermes shareholders re

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Guidelines to prevent youth baseball injuries need more muscle

Free Covid tests will again be offered to all U.S. households

focus

Why the quest to eradicate polio has stumbled

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

AI models in health care face new federal disclosure requirements

What causes an itch? Researchers may have solved the mystery

SCOTUS to consider access to abortion pill mifepristone

People with substance use disorder deserve online privacy

focus

Wikipedia

hotspot

leisure time